A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Zolmitriptan (ZOMIG)

Serotonin-1b and Serotonin-1d Receptor Agonist class · 10 generic manufacturers · 28 ANDAs filed at FDA.

First FDA approval2013-05-14
Generic availableYes · 10 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$11.4M in CY2024 Part D spend79K claims · 25K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.05/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.49
Across all dosage forms in distribution.
Highest NADAC
$2.38
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Zolmitriptan used for?

Zolmitriptan is a Serotonin-1b and Serotonin-1d Receptor Agonist medication tracked in Medicare Part D.

Is there a generic for Zolmitriptan?

Yes. 28 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Zolmitriptan?

Across 329 Part D plans, Zolmitriptan averages $1.49/unit (NADAC). Lowest available: $1.05/unit. Highest in distribution: $2.38/unit.

Is Zolmitriptan on the FDA shortage list?

No. Zolmitriptan is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Serotonin-1b and Serotonin-1d Receptor Agonist3 alternatives in D1
01
Eletriptan Hydrobromide
Brand: Relpax
$1.87Lowest NADAC
7Generic mfrs
$13.0MCY24 Part D spend
Compare →
02
Rizatriptan
Brand: MAXALT
$0.484Lowest NADAC
7Generic mfrs
$26.3MCY24 Part D spend
Compare →
03
Sumatriptan
Brand: IMITREX
$0.258Lowest NADAC
21Generic mfrs
$83.8MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.